Page 241 - 2021_04-Haematologica-web

Multicenter study of romiplostim for CIT
26.Consensus Committee of Chemotherapy Induced Thrombocytopenia CSoCO. [Consensus on clinical diagnosis, treatment and prevention management of chemother- apy induced thrombocytopenia in China(2018)]. Zhonghua Zhong Liu Za Zhi. 2018;40(9):714-720.
27. Demeter J, Istenes I, Fodor A, et al. Efficacy of romiplostim in the treatment of chemotherapy induced thrombocytopenia (CIT) in a patient with mantle cell lym- phoma. Pathol Oncol Res. 2011;17(1):141- 143.
28.Villano JL, Letarte N, Yu JM, Abdur S, Bressler LR. Hematologic adverse events associated with temozolomide. Cancer Chemother Pharmacol. 2012;69(1):107- 113.
29. Wun T, White RH. Epidemiology of cancer- related venous thromboembolism. Best Pract Res Clin Haematol. 2009;22(1):9-23. Khorana AA, Dalal M, Lin J, Connolly GC. Incidence and predictors of venous throm- boembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States. Cancer.
2013;119(3):648-655.
31. Haas SK, Freund M, Heigener D, et al. Low-
molecular-weight heparin versus placebo for the prevention of venous thromboem- bolism in metastatic breast cancer or stage III/IV lung cancer. Clin Appl Thromb Hemost. 2012;18(2):159-165.
32. Carrier M, Abou-Nassar K, Mallick R, et al. Apixaban to prevent venous thromboem- bolism in patients with cancer. N Engl J Med. 2019;380(8):711-719.
30.
haematologica | 2021; 106(4)
1157